US 9,849,128 B2 · Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells

Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells

AssigneesUnity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, The John Hopkins University

InventorsRemi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon

Life of this patent

Estimating the term…

Abstract

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Claims15

Dependent claims

A unit dose of a pharmaceutical composition that contains an amount of the compound shown in Formula (I):

or a pharmaceutically acceptable salt thereof,
wherein the composition contains a formulation of the compound suitable for administration into an osteoarthritic joint of a subject in need thereof;
and
wherein the formulation of the composition and the amount of the compound in the unit dose configure the unit dose to be effective in treating the osteoarthritic joint by decreasing the severity of one or more signs or symptoms of osteoarthritis in the joint without causing adverse effects when administered to the joint as a single dose.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

15/455,575Filed 10 Mar 2017 · continuation

Priority

28 Jan 2014

Published

US 2017/0196857 A113 Jul 2017

Granted

26 Dec 2017

Term ends

Not estimatedThe source records don’t support an estimate.

Classification27 codes

A61K 31/496
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: non-condensed piperazines…
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 9/0073
Pulmonary tract; Aromatherapy: sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
A61K 31/404
Condensed with carbocyclic rings, e.g. carbazole: indoles, e.g. pindolol

Family

Application61/932,704Us provisional application · filed 28 Jan 2014

Application61/932,711Us provisional application · filed 28 Jan 2014

Application61/979,911Us provisional application · filed 15 Apr 2014

Application62/002,709Us provisional application · filed 23 May 2014

Application62/042,708Us provisional application · filed 27 Aug 2014

Application62/044,664Us provisional application · filed 2 Sep 2014

Application62/057,820Us provisional application · filed 30 Sep 2014

Application62/057,825Us provisional application · filed 30 Sep 2014

Application62/057,828Us provisional application · filed 30 Sep 2014

Application62/061,627Us provisional application · filed 8 Oct 2014

Application62/061,629Us provisional application · filed 8 Oct 2014

PCT/US2015/013387Parent of this continuation · filed 28 Jan 2015

US 2017/0196857 A1Pre-grant publication · published 13 Jul 2017

Application15/114,762Parent of this continuation

US 2016/0339019 A1Published application

US 2017/0224680 A2Published application

US 9,993,472 B2Related patent

US 9,849,128 B2This patent

From the US filing history. Foreign family members aren’t listed.